难治及复发性恶性血液病采用三氧化二砷联合化疗对预后影响

目的：观察三氧化二砷联合化疗方案治疗难治及复发性恶性血液病的效果。方法：随机从我院2009年6月一2014年6月收治的难治及复发性恶性血液病患者中抽取60例作为研究对象，根据治疗方案将其分为对照组和观察组，每组各30例。其中对照组使用单纯化疗方案治疗，观察组则使用三氧化二砷联合化疗的方案治疗，对比两组的临床效果和毒性反应。结果：经对比，观察组患者的总有效率为86．67％，显著高于对照组的66．67％，差异具有统计学意义（P〈0．05）。同时，观察组的毒性反应发生率为30％，显著低于对照组的66．67％，差异具有统计学意义（P〈0．05）。结论：对难治及复发性恶性血液病采用三氧化二砷联合化疗治疗具有显著疗效，降低不良反应，有助于改善患者的预后。

Refractory and recurrent malignancies with arsenic trioxide MDT analysis influence on prognosis

Objective： To explore the use of arsenic trioxide and combination in the treatment of refractory and the prognosis of recurrent malignancies effects and adverse reactions. Methods： Random from our hospital in June 2009～June 2014 patients with refractory and recurrent malignancies treated were extracted 60 cases as the research object, according to the treatment plan will be divided into control group and observation group, 30 cases in each group. , including control group using pure chemotherapy regimen for observation group joint solution with arsenic trioxide and chemotherapy treatment, compared two groups of clinical effect and toxic reaction. Results： By contrast, the observation group the total effective rate of the patients were 86.67%, significantly higher than that of control group 66.67%, and the difference is statistically significant（P〈0.05）. Incidence of toxic effects of at the same time, the observation group was 30%, significantly lower than the control group 66.67%, and the difference is statistically significant （P〈0.05）. Conclusion： The refractory and recurrent malignancies with arsenic trioxide combination therapy and chemotherapy scheme have significant curative effect, reduce adverse reactions, and help to improve the prognosis of patients with effect.